Key highlights
- Mean splicing correction of 46.5% at 10 mg/kg represents a record for multiple dose studies in DM1
- Four out of six participants in the cohort achieved splicing improvement greater than 50% at Week 13
- Functional improvements observed in hand opening time, grip strength, and mobility measures
- Cash position of $104.8 million as of September 2026 provides operational runway into 2028
- Highest dose cohort of 12.5 mg/kg is fully enrolled with data readout expected in 1H 2027
Clinical Trial Progress
PepGen Inc. announced positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 clinical trial, evaluating the candidate PGN-EDODM1 for myotonic dystrophy type 1. The study reached its primary biological objective, demonstrating a mean splicing correction of 46.5% at the 13-week mark. This result represents the highest reported correction level in a multiple-dose study for this patient population to date. Beyond molecular data, participants showed functional improvements in hand opening time, grip strength, and mobility tests. Management confirmed that the 12.5 mg/kg cohort is already fully enrolled, with further data expected during the first half of 2027.
Biological Milestone and Safety
The mean splicing correction of 46.5% achieved in this cohort is a critical technical milestone, as it exceeds biological benchmarks previously established in other DM1 trials. Myotonic dystrophy type 1 is characterized by toxic RNA sequestration that prevents proper protein production; correcting the splicing mechanism is intended to restore normal cellular function in muscle tissues. The 10 mg/kg dose was generally well-tolerated among participants, with no reports of serious adverse events or dose-limiting toxicities. These results support the company’s strategy to evaluate higher dosages to potentially maximize therapeutic efficacy while maintaining a manageable safety profile.
Financial Performance and Runway
Financially, PepGen maintains a robust balance sheet with $104.8 million in cash and cash equivalents as of September 30, 2026. The company reported a net loss of $21.4 million for the third quarter, driven largely by $16.4 million in research and development expenses as clinical programs transitioned to higher dose cohorts. General and administrative costs were $6.9 million for the same period. Based on current projections, the existing capital is sufficient to fund the company’s operations and clinical milestones through 2028, providing a runway that extends well beyond the anticipated readout of the highest-dose cohort.
Up 75.3% since our story on 10 Nov: $2.39 when we broke it → $4.19 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $2.70 |
|---|---|
| 20 Oct | $2.87 |
| 21 Oct | $2.72 |
| 22 Oct | $2.70 |
| 23 Oct | $2.52 |
| 26 Oct | $2.49 |
| 27 Oct | $2.60 |
| 28 Oct | $2.53 |
| 29 Oct | $2.41 |
| 30 Oct | $2.36 |
| 2 Nov | $2.35 |
| 3 Nov | $2.46 |
| 4 Nov | $2.45 |
| 5 Nov | $2.32 |
| 6 Nov | $2.47 |
| 9 Nov | $2.39 |
| 10 Nov | $4.61 |
| 11 Nov | $5.26 |
| 12 Nov | $5.04 |
| 13 Nov | $4.36 |
| 16 Nov | $4.19 |
Industry Context and Regulatory Outlook
The landscape for myotonic dystrophy type 1 treatments is an area of significant clinical focus, with an estimated 40,000 patients in the United States currently lacking disease-modifying therapies. PepGen competes with other biotechnology firms developing RNA-targeted candidates, but its Enhanced Delivery Oligonucleotide platform is designed specifically to overcome tissue-delivery barriers in muscles. While the company is currently under a partial clinical hold by the U.S. FDA due to nonclinical mouse findings, it is actively conducting the necessary studies to resolve these concerns. Success in the FREEDOM2 trial is vital for the company's regulatory path toward an end-of-Phase 2 meeting scheduled for late 2027.
Management commentary
“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution. We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”
| Share price | $2.39 |
|---|---|
| Market cap | $166M |
| 1-month price change | +0.42% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by PepGen Inc. announcing positive Phase 2 clinical results and Q3 2026 financial performance.
Track PepGen Inc. live
Get the next PepGen Inc. SEC filing seconds after it lands.




